Agenda
Endgame 2025: learning from the past, envisioning the future
Day 1, Tuesday, August 12, 2025
Shuttle service to NVRC
Arrival, registration, and coffee
Summit introduction
- Stephen Thomas, MD. Upstate Global Health Institute
Welcome address
- Alan Rothman, MD. University of Rhode Island
Session 1. Reality check: dengue situation on the ground.
Session objective: to discuss and review the current state of dengue around the world
- Julio Croda. Fundação Oswaldo Cruz/Federal University of Mato Grosso do Sul/Yale School of Public Health (20 min)
- Tahmina Shirin, PhD , Institute of Epidemiology, Disease Control & Research (IEDCR)
- John Waitumbi, DMV, PhD. Kenya Medical Research Institute/WRAIR-Africa (20 min)
- Bridget Wills, FRCPCH, DM. University of Oxford (Discussion (30 min))
Coffee break
Session 2. How did we end up here: what are the drivers for the most recent global dengue surge (2023-present)?
Session objective: to discuss and review the factors associated with the record-breaking dengue outbreaks observed 2023 – present
- Henrik Salje, PhD , University of Cambridge
- Kathryn Anderson, MD, PhD, CTropMed. SUNY Upstate Medical University (20 min)
- Rebecca Christofferson, MApSt, PhD , Louisiana State University
Lunch Break (boxed lunch)
Session 3. What is the true global burden of dengue?
Session objective: to discuss and review metrics and tools for assessing the global medical, social, and economic impact of dengue
- Shirin Kalimuddin, MBBS, MRCP. Singapore General Hospital, Duke-NUS, Singapore (20 min)
- Angkana Huang, PhD. Pathogen Dynamics Unit, University of Cambridge (20 min)
- Jing Shen, PhD. Takeda (20 min)
- Derek Cummings, PhD. The Johns Hopkins University (Discussion (20 min))
Coffee Break
Session 4. Back to basics: vectors and vector control in the context of a dengue endgame
Session objective: to discuss the contribution of vector biology, ecology, and anti-vector countermeasures in the pursuit of a dengue endgame
- Jason Rasgon, PhD , Pennsylvania State University
- Albert Ko, PhD , Yale University, Raj and Indra Nooyi Professor of Public Health
- Fabiano Oliveira, MD, PhD , National Institute of Health, National Institute of Allergy and Infectious Diseases, Laboratory of Malaria and Vector Research
Break
Session 5. Latest-breaking science topics
Session objective: Presentations selected from abstract submissions
- Thomas-Wolf Verdonckt, PhD , Institute of Tropical Medicine in Antwerp
- Youngsuk Ko, PhD. Yale School of Public Health (15 min)
- Mayuri Sharma, PhD. Takeda (15 min)
- Emilie Finch, PhD. University of Cambridge (15 min)
- Eugenia Z Ong, PhD. Duke-NUS Medical School (15 min)
- Ana G. Madrigal. University of Vermont (15 min)
Happy hour and poster session (Grand Hall)
Day 2, Wednesday, August 13, 2025
Shuttle service to NVRC
Arrival and coffee
Session 6. Advanced stage countermeasure update: vaccines
Session objective: to review and discuss the state of advanced-stage dengue countermeasures. Presentations from advanced-stage countermeasure developers.
- Derek Wallace, MBBS. Takeda Vaccines (20 min)
- Germán Áñez, MD, FIDSA. Merck & Co., Inc. (20 min)
- Steffen Mueller, PhD. Codagenix Inc. (20 min)
- In-Kyu (Q) Yoon, MD , International Vaccine Institute
Session 7. Advanced stage countermeasure update: therapeutics
Session objective: to review and discuss the state of advanced-stage dengue countermeasures. Presentations from advanced-stage countermeasure developers.
- Stephanie Moquin, PhD. Novartis, USA (20 min)
- Herbert Slade, MD, FAAAAI, FWHS. Island Pharmaceuticals (20 min)
- Michael, MD, PhD. Walter Reed Army Institute of Research (Discussion (20 min))
Coffee Break
Session 8. Re-evaluating immune correlates of protection and pathogenesis and their role in the pathway to a dengue endgame.
Session objective: to discuss and review the scientific and regulatory implication of re-evaluating immune correlates of protection and pathogenesis
- Leah Katzelnick, PhD, MPH. National Institute of Allergy and Infectious Diseases (20 min)
- Eva Harris, PhD , University of California, Berkeley
- Taia Wang, MD PhD , Stanford University
- Ashley St. John, PhD. Duke-NUS Medical School (20 min)
- Sean Diehl, PhD , University of Vermont
Lunch Break (boxed lunch)
Session 9. Are all DENV strains/serotypes created equal?
Session objective: to discuss dengue virus genetic evolution and its impact on dengue epidemiology and clinical outcomes, and its influence of the pathway to a dengue endgame.
- Eng Eong Ooi, MD, PhD. Duke-NUS, Singapore (20 min)
- Chantal Vogels, PhD , Yale School of Public Health
- Alan Barrett, PhD. University of Texas Medical Branch (Discussion (30 min))
Coffee Break
Session 10. What is severe dengue and how do we quantify dengue severity?
Session objective: to collaboratively define a clear and actionable metric for assessing dengue severity that can be universally applied in pursuit of a dengue endgame
- Bridget Wills, FRCPCH, DM. University of Oxford (20 min)
- Morgan Marks, PhD. Merck & Co. Inc. (20 min)
- Daniel Munblit, PhD. King's College London (20 min)
- Jenny Low Guek Hong, MD. Singapore General Hospital & Duke-NUS Medical School (Discussion (20 min))
Break
Session 11. Advances in human challenge models
- Beth Kirkpatrick, MD. University of Vermont College of Medicine (20 min)
- Kirsten E Lyke, MD. University of Maryland, School of Medicine (20 min)
- Ruian Ke, PhD. Los Alamos National Laboratory (20 min)
- Heather Friberg, PhD. Walter Reed Army Institute of Research (Discussion (30 min))
Group photo and closing remarks, Day 2
Social event: Syracuse Marriott
Day 3, Thursday, August 14, 2025: putting the pieces together
Shuttle service to NVRC
Arrival and coffee
Session 12. Building a path forward: what is the dengue endgame, and how do we get there?
Session objective: To discuss what to identify and discuss which relationships and leadership roles are needed to achieve a dengue endgame
- Jenny Low Guek Hong, MD. Singapore General Hospital & Duke-NUS Medical School (20 min)
- Andre Siqueira, MD, PhD , Drugs for Neglected Diseases initiative
- In-Kyu (Q) Yoon, MD , International Vaccine Institute
- Stephen Thomas, MD. Upstate Global Health Institute (Discussion (30 min))
Coffee Break
Session 13. Panel discussion: looking in the mirror: revisiting preconceptions, assumptions, and dogma in dengue ecology, immunology, and epidemiology
Session objective: to review and discuss preconceptions, assumptions, and dogma in dengue and their impact on progress towards a dengue endgame
- Alan Rothman, MD. University of Rhode Island
- Eng Eong Ooi, MD, PhD. Duke-NUS, Singapore
- Henrik Salje, PhD , University of Cambridge
- Stephen Thomas, MD. Upstate Global Health Institute
- Eva Harris, PhD , University of California, Berkeley
- Leah Katzelnick, PhD, MPH. National Institute of Allergy and Infectious Diseases
- Adam Waickman, PhD. SUNY Upstate Medical University (Moderator)
- Kathryn Anderson, MD, PhD, CTropMed. SUNY Upstate Medical University (Moderator)
Closing remarks
KG Tan Auditorium, National Veterans Resource Center – Syracuse, NY
Thank You Sponsors
-
Presenting Sponsor
-
Partnership Sponsor
-
General Sponsor
